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ABSTRACT
Objective: The aim of this study was to develop and evaluate a pedagogical tool to enhance
the understanding of a checklist that evaluates reports of nonpharmacological trials (CLEAR
NPT).
Design: Paired randomised controlled trial.
Participants: Clinicians and systematic reviewers.
Interventions: We developed an Internet-based computer learning system (ICLS). This
pedagogical tool used many examples from published randomised controlled trials to
demonstrate the main coding difficulties encountered when using this checklist.
Randomised participants received either a specific Web-based training with the ICLS
(intervention group) or no specific training.
Outcome measures: The primary outcome was the rate of correct answers compared to a
criterion standard for coding a report of randomised controlled trials with the CLEAR NPT.
Results: Between April and June 2006, 78 participants were randomly assigned to receive
training with the ICLS (39) or no training (39). Participants trained by the ICLS did not differ
from the control group in performance on the CLEAR NPT. The mean paired difference and
corresponding 95% confidence interval was 0.5 ( 5.1 to 6.1). The rate of correct answers did not
differ between the two groups regardless of the CLEAR NPT item. Combining both groups, the
rate of correct answers was high or items related to allocation sequence (79.5%), description of
the intervention (82.0%), blinding of patients (79.5%), and follow-up schedule (83.3%). The rate
of correct answers was low for items related to allocation concealment (46.1%), co-
interventions (30.3%), blinding of outcome assessors (53.8%), specific measures to avoid
ascertainment bias (28.6%), and intention-to-treat analysis (60.2%).
Conclusions: Although we showed no difference in effect between the intervention and
control groups, our results highlight the gap in knowledge and urgency for education on
important aspects of trial conduct.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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PLoS CLINICAL TRIALSINTRODUCTION
Assessing the quality of reports of randomised controlled
trials (RCTs) is particularly important for clinicians’ critical
appraisal of the health-care literature and for systematic
reviewers [1]. In fact, evidence suggests that inadequate
reporting is associated with biased treatment effect estimates
[2–5]. The QUOROM (Quality of Reporting of Meta-analysis)
Statement [6] recommends reporting the criteria and the
process used for quality assessment of trials included in a
systematic review or meta-analysis. Similar recommendations
can also be found in section 6 of the Cochrane Handbook for
Systematic Reviews of Interventions [7]. Moja et al. recently
reported that the methodological quality of primary studies
was assessed in 854 of 965 systematic reviews (88.5%) [8].
Quality assessment is often achieved by the use of checklists
or scales, such as the Veerhagen list or the Jadad scale [9–12].
In the ﬁeld of nonpharmacological treatment (NPT), a
checklist—the checklist to evaluate a report of a non-
pharmacological trial (CLEAR NPT)—was developed to assess
the quality of RCTs included in meta-analysis [13]. This
assessment tool was developed using the Delphi Consensus
method, with consensus of 55 international experts (clini-
cians, methodologists, and members of the Cochrane collab-
oration). It includes ten items and ﬁve subitems (Text S1) and
is published with a user’s guide explaining each item in detail
(Text S2).
Reproducibility issues have been raised regardless of the
chosen quality tool [14], because inconsistently deﬁned items
such as blinding [15], dropout and withdrawals [16], or an
intention-to-treat analysis [17–20] are used and are poorly
understood by reviewers. To overcome these issues, some
authors have developed speciﬁc guidelines for some quality
tools, which provide detailed explanation on scoring each
item [9]. Further, a training session is recommended for all
reviewers [9]. Despite these recommendations, Clark et al.
showed that in a study of reviewers with face-to-face training
sessions before scoring reports of RCTs, the interrater
agreement for the Jadad scale— one of the simplest quality
tools—was poor (kappa 0.37 to 0.39) [16]. Therefore, other
pedagogical tools to improve the understanding and the
reproducibility of these scales and checklists are needed.
Objectives
To improve the understanding of the CLEAR NPT, we
developed an Internet-based computer learning system
(ICLS). This pedagogical tool offers, through the use of
practical examples from RCTs, a problem-based approach to
solving the main coding difﬁculties encountered when using
the CLEAR NPT. We chose a Web-based tool as it is more
feasible than face-to-face meetings and can be tailored to
individuals’ answers. To evaluate the impact of the ICLS on
proper coding with the CLEAR NPT, we carried out an RCT
comparing ICLS to no speciﬁc training.
METHODS
Development of ICLS
The ICLS was developed in three steps: construction, design,
and validation.
Construction of the ICLS database. To develop the ICLS,
we identiﬁed difﬁculties encountered when using the CLEAR
NPT (e.g., lack of comprehension of the items and lack of
consistency in the deﬁnition of an item) and selected passages
from RCTs that could be include in the ICLS.
For this purpose, we selected a panel of reports of RCTs
assessing NPT (Text S3).
Two reviewers, one involved in the elaboration of the
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Understanding of a Quality Checklist
Editorial Commentary
Background: A key part of the practice of evidence-based medicine
(essentially, the appropriate use of current best evidence in determining
care of individual patients) involves appraising the quality of individual
research papers. This process helps an individual to understand what has
been done in a clinical research study, and to decipher the strengths,
limitations, and importance of the work. Several tools already exist to
help clinicians and researchers to assess the quality of particular types of
study, including randomised controlled trials. One of these tools is called
CLEAR NPT, which consists of a checklist that helps individuals to
evaluate reports of nonpharmacological trials (i.e., trials not evaluating
drugs but other types of intervention, such as surgery). The researchers
who developed CLEAR NPT also produced an Internet-based computer
learning system to help researchers use CLEAR NPT correctly. They
wanted to evaluate to what extent this learning system helped people
use CLEAR NPT and, therefore, carried out a randomised trial comparing
the learning system to no specific training. A total of 78 health
researchers were recruited as the ‘‘participants’’ in the trial, and 39 were
randomised to each trial arm. Once the participants had received either
the Internet training or no specific training, they used CLEAR NPT to
evaluate reports of nonpharmacological trials. The primary outcome was
the rate of ‘‘correct’’ answers that study participants gave using CLEAR
NPT.
What the trial shows: The researchers found that the results on the
primary outcome (rate of correct answers given by study participants)
did not differ between the study arms. The rate of correct answers for
individual items on the checklist also did not seem to differ between
individuals receiving Internet training and those receiving no specific
training. When looking at the scores for individual items, combined
between the two study arms, participants scored highly on their
appraisal of some aspects of trial design (such as generation of
randomisation sequences and descriptions of blinding and the
intervention) but poorly on other items (such as concealment of the
randomisation sequence).
Strengths and limitations: Key strengths of this study include the
randomised design and that the trial recruited enough participants to
test the primary hypothesis. The failure to find a significant difference
between study arms in this trial was likely not due to a lack of statistical
power. One limitation of the study is that the group of researchers who
participated were already fairly experienced in assessing trial quality at
the start, and this may explain why no additional effect of the computer-
based learning system was seen. It is possible that the training system
may have some benefit for individuals who are less experienced in
evaluating trials. A further possible limitation may be that there was a
small imbalance at randomisation, with slightly more experienced
researchers being recruited into the arm receiving no specific training.
This imbalance might have underestimated the effect of the training
system.
Contribution to the evidence: The researchers here report that this
study is the first they are aware of that evaluates a computer-based
learning system for improving assessment of the quality of reporting of
randomised trials. The results here find that this particular tool did not
improve assessment. However, the results emphasise that training
should be considered an important part of the development of any
critical appraisal tools.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.CLEAR NPT (IB) and one using the CLEAR NPT for the ﬁrst
time (LF), independently assessed these reports using the
CLEAR NPT items. A meeting followed in which the ratings
were compared. This session allowed for the identiﬁcation of
disagreement and difﬁculties in understanding CLEAR NPT
items. According to the difﬁculties in understanding CLEAR
NPT items for this panel, the two reviewers selected speciﬁc
passages that were either adequately reported, inadequately
reported, or a frequent cause for disagreement.
Although reviewers can be non-native English speakers, the
computer learning system was written in English. In fact, most
papers included in systematic reviews and meta-analyses are
published in English. Consequently, it seemed logical to use
the same language in the learning system.
Designing the ICLS program. We designed a computer
program following the model of a knowledge-based expert
system [21–23]. The main principles of this program are
reported in Figure S1. After proposing a short passage from a
clinical trial previously selected for the database, the ﬁrst
item is put forward for participants with its modalities of
answers (e.g., yes/no/unclear). Depending on their answers,
users are led on different pathways drawn from the CLEAR
NPT user’s guide: (1) If the answer is correct, users are
directed to a Web page conﬁrming the correct answer for this
item, which also provides a detailed explanation and
computerized version of the user’s guide; (2) If the answer is
incorrect, participants are asked a list of subquestions to help
them determine where they made a mistake. The system is
therefore self-correcting and enhances understanding of
incorrect participant answers. Each participant has a mini-
mum of two passages to refer to for each item and one last
passage if they answered incorrectly for their second passage.
Validation of the ICLS. The computer learning system was
validated by one of the authors (PR) who conﬁrmed the
validity of the answers and pathways of the ICLS. The ICLS
was also tested by a group of three people who had never used
CLEAR NPT.
The RCT: Influence of the ICLS on Coding with the
CLEAR NPT
We designed an RCT comparing two groups of participants
receiving either the user’s guide and speciﬁc training with the
ICLS (intervention group) or a user’s guide with no speciﬁc
training (control group) to assess the impact of the ICLS. In
France, the submission of a trial to an ethics committee is
deﬁned according to the public health law of August 2004,
which requires the submission of protocols for review by an
ethics committee only if the trial involves patients, and if the
treatment is not administered in clinical practice but involves
a speciﬁc treatment or speciﬁc investigation. Trials aimed at
educating medical doctors or reviewers are not required to
submit the protocol to an ethics committee. Participants in
our study were previously informed of the trial, they could
withdraw from the trial if they wished, and they were
informed of the results of the trial upon completion.
Participants. Members from three different categories of
participants were invited by e-mail to participate in the RCT:
(1) Members of Health Technology Assessment international
(HTAi) (n ¼ 430) were selected for their knowledge of quality
assessment. HTAi is an international society for the promo-
tion of health technology assessment and holds international
conferences and forums. Members are involved in the ﬁeld of
evaluation, and some perform systematic reviews; (2) direc-
tors of Evidence-based Practice Centers (EPC) (n ¼ 13) who
develop systematic reviews and technology assessments on
topics relevant to clinical, social science/behavioral, econom-
ic, and other healthcare organization and delivery issues; and
(3) corresponding authors of meta-analyses of NPT published
between 1 January 2004 and 3 March 3 2006 (n ¼ 100).
Design. Participants were randomised in pairs to be
evaluated at the end on the same report (i.e., each report
was evaluated with CLEAR NPT by one participant in both
groups). This design allowed for assessing reviewers’ under-
standing of several articles. A smaller panel would decrease
the variability of the results. However, the quality of
reporting of the trial is a critical issue in quality assessment,
and we would not have been able to formulate conclusions on
the basis of a smaller panel.
Randomisation: Sequence generation. The paired random-
isation procedure was centralized and performed by means of
a computer-generated list stratiﬁed on the degree of
expertise in the ﬁeld of meta-analysis by a statistician of the
epidemiology department performing the trial.
Randomisation: Allocation concealment. The investigators
did not have access to this procedure. Participants were
considered ‘‘experts’’ if they had been involved in the
publication of a meta-analysis indexed in PubMed.
Randomisation: Implementation. The randomisation was
implemented on the Web site by a computer scientist (LR).
Participants could not foresee their assignment until the
beginning of the intervention. They received a personal log-
in account number by e-mail that directed them to an
appropriate Web page depending on their randomisation
group. Each pair of participants assessed one report of a
randomised trial. A waiting list of participants who agreed to
be randomised was compiled to replace withdrawals.
Interventions. Participants in both groups received an e-
mail containing the CLEAR NPT checklist and the user’s
guide. For each item in the CLEAR NPT, the user’s guide
explained its meaning and how to score it. The checklist and
user’s guide are detailed in Texts S1 and S2.
The control group received only the user’s guide and was
asked to assess one report of a randomised trial using the
CLEAR NPT, whereas the experimental group was directed to
the ICLS and also assessed one report of a randomised trial
after completing the training.
Blinding (masking). Participants could not be blinded to
their randomisation group because of obvious differences in
terms of intervention.
Panel of reports assessed by the participants. To evaluate
the performance of participants in using CLEAR NPT, we
selected a panel of RCTs by searching PubMed for all RCTs
assessing NPTs published between 1 January 2005 and 31
March 2006, in the following journals: New England Journal of
Medicine, the Journal of the American Medical Association, Lancet,
Annals of Internal Medicine, BMJ, Annals of Surgery, British Journal
of Surgery, Annals of Surgical Oncology, Archives of General
Psychiatry, American Journal of Psychiatry, Journal of Clinical
Psychiatry, Physical Therapy, Supportive Care in Cancer, and
Archives of Physical Medicine and Rehabilitation.
A total of 200 reports were identiﬁed. Among these, some
reports were randomly selected to be evaluated. Half of these
reports assessed a surgical procedure, and half assessed
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Understanding of a Quality Checklistanother NPT such as rehabilitation, psychotherapy, or
devices. The selected articles are described in Text S4.
Outcomes. Three reviewers (LF, IB, and PR) independently
assessed the selected reports. All discrepancies were dis-
cussed, and the user’s guide was consulted to obtain a
consensus for appropriate answers for each item of the
CLEAR NPT. This consensus was considered as the criterion
standard.
At the end of the training program, participants had to
assess one of the selected reports of an RCT using the CLEAR
NPT and complete a qualitative assessment of the ICLS. The
primary outcome was the rate of correct answers on the ten
main items of each group for the ﬁnal assessment compared
to the criterion standard. Secondary outcomes were the rate
of correct answers for each item and a qualitative assessment
of the ICLS by the survey participants, completed after
fulﬁlling the training program.
Sample size. A sample size of 38 pairs will have 85%
statistical power to detect a difference in means of 10% (e.g.,
a mean rate of correct responses of 70% in the intervention
group and 60% in the control group), assuming a standard
deviation of differences of 20%, using a paired Student’s t-
test with a 0.05 two-sided signiﬁcance level.
Statistical methods. The mean rate of correct answers of
participants to the criterion standard was compared by a
paired Student’s t-test. The ‘‘per item rate’’ of correct answers
to the criterion standard was compared by use of a McNemar
test for paired dichotomous data and with Yates correction
when appropriate. A p-value   0.05 was considered statisti-
cally signiﬁcant, and all tests were two-sided. Statistical
analyses involved the use of SAS 9.1 (SAS Institute, http://
www.sas.com).
Results
Participant Flow
Figure 1 shows the ﬂow of participants through the trial. Of
the 543 people invited to participate, 88 agreed to participate
(16%), and 78 were randomised, 39 allocated to receive
training with the ICLS and 39 to receive no training. A total
of nine participants did not complete the survey and were
replaced by waiting list participants. The main reasons for
withdrawals were not having time to complete the survey (i.e.,
spontaneous withdrawal, n ¼ 3), not understanding the
program (n ¼ 1), not completing the survey after ﬁve
reminders (n ¼ 4), and not ﬁnishing the training (n ¼ 1).
Numbers Analysed
A total of 78 participants completed the ﬁnal assessment and
were analysed.
Recruitment
Between April and June 2006, 78 participants were recruited
Baseline Data
Baseline characteristics are described in Table 1. The number
of meta-analyses published on PubMed was similar in each
group. However, despite stratifying on expertise with meta-
analysis, the declared expertise was higher in the control
group (84.2%) than in the intervention group (65.8%) (Table
1). Among the participants four, had already used the CLEAR
Figure 1. Flow Chart of Participants
doi:10.1371/journal.pctr.0020022.g001
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Understanding of a Quality ChecklistNPT. The description of the ICLS and panel of articles used
for ﬁnal assessment is described in Text S5.
Outcomes and Estimation
Primary outcome. Results on the primary outcome results
are reported in Figure 2. The performance of participants
trained by the ICLS did not differ from that of the control
group. The mean paired difference and corresponding 95%
conﬁdence interval was 0.5 ( 5.1 to 6.1).
Secondary outcomes. Regardless of the CLEAR NPT
checklist item considered, the rate of correct answers did
not differ between the two groups (Table 2). Overall, taking
into consideration all participants, the rate of correct
answers was high for the items related to the allocation
sequence (79.5%), the description of the intervention
(82.0%), blinding of patients (79.5%), and follow-up schedule
(83.3%). The rate of correct answers was low for items related
to the allocation concealment (46.1%), co-interventions
(30.3%), blinding of outcome assessors (53.8%), speciﬁc
measures to avoid ascertainment bias (28.6%) and inten-
tion-to-treat analysis (60.2%).
DISCUSSION
Interpretation
To our knowledge this study is the ﬁrst to develop and
evaluate a computer learning system to improve the under-
standing of a checklist for assessing the quality of reporting of
RCTs. Moher et al. reported an annotated bibliography of
scales and checklists developed to assess quality [9]. Only a
few quality tools have clear users’ guides to standardize the
understanding of the items, and none are provided with a
speciﬁc training program. This computer learning system is
Internet-based so it offers greater ﬂexibility in training time
and sequencing. We assessed the impact of the ICLS in
assessing reports of RCTs of NPTs. Although participants
were satisﬁed with the quality of the computer program
(interface, readability of the text, and information delivered),
training with the ICLS did not have a signiﬁcant and relevant
impact in terms of rate of correct answers compared with a
criterion standard. These results highlight the difﬁculties in
training and are consistent with systematic reviews showing
that for peer review, referees’ training did not improve the
quality of the review [24,25]. However, in this trial we cannot
determine whether the problem was related to the quality
instrument or to the teaching tool.
Overall Evidence
Some factors can be offered to explain the lack of efﬁcacy of
the ICLS. First, most of the participants had been involved in
the publication of at least one meta-analysis. Consequently,
this population has some level of expertise in quality
assessment and probably needs more speciﬁc training than
naı ¨ve participants. Consequently, we should probably assess
the impact of the ICLS on inexperienced participants to
determine its effect on the performance of this population.
Second, the ICLS trained participants similarly for each
item of the checklist. However, our results highlighted that
lack of reproducibility concerned only some items of the
checklist. Items related to the allocation sequence generation,
description of interventions, blinding of patients or health-
care providers, and follow-up schedule were well rated, with
.......................................................................................................................................................................................
Table 1. Baseline Characteristics of Participants
Characteristics Subcategory Intervention Control
Age, mean 6 standard deviation years 40.4 6 9.8 y, n ¼ 37 39.7 6 10.2 y, n ¼ 36
Profession n ¼ 39 n ¼ 39
Clinicians 18% (46.2%) 13% (33.3%)
Systematic reviewers 19% (48.7%) 25% (64.1%)
Others 2% (5.1%) 1% (2.6%)
Number of meta-analyses published on PubMed n ¼ 39 n ¼ 39
0 21% (53.8%) 21% (53.8%)
One or more 18% (46.2%) 18% (46.2%)
Number of meta-analyses performed reported by participants n ¼ 38 n ¼ 38
0 13% (34.2%) 6% (15.8%)
Two 4% (10.5%) 2% (5.2%)
2–5 13% (34.2%) 18% (47.4%)
.5 8% (21.1%) 12% (31.6%)
Experience in using CLEAR NPT n ¼ 36 n ¼ 38
Yes 2% (5.6%) 2% (5.3%)
doi:10.1371/journal.pctr.0020022.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 2. Dot Plot of the 39 Paired Differences
Each plot represents a paired difference (i.e., the rate of correct responses of
the intervention respondent minus the rate of correct responses of the
control respondent). Observation to the left of 0 favours the control group
and observation to the right of 0 favours the intervention group.
doi:10.1371/journal.pctr.0020022.g002
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Understanding of a Quality Checklistmore than 80% correct answers. These items probably need
little or no training for proper scoring. Consequently, the
ICLS could be tailored and provide more training on various
examples for items with low understanding.
Third, some examples of RCTs used to question and train a
reviewer when using the CLEAR NPT might not be adequate.
In fact, some examples with a high rate of correct answers
were probably less informative, whereas other examples with
a low rate of correct answers were probably more valuable for
educating reviewers.
Finally, because participants were not blinded to the aim of
the study, we cannot exclude the risk of bias with participants
in the control group relying on the user’s guide with more
attention than they would do in usual practice.
Although the ICLS had no signiﬁcant impact on RCT
reviewers’ performance, most assessment tools do not have
any instructions in how to use the quality assessment scale [9–
12], whereas the training can be viewed as proactive and is
recommended as an important component in the presenta-
tion of any new instrument development. Our results high-
lighted the lack of consistent understanding of some items.
These results could be linked to: (1) the wording of the items
of the checklist that could be slightly modiﬁed; (2) a lack of
consensus on the deﬁnition of some items; and (3) an
inadequate reporting of the trial that could have been
confusing for reviewers. Lack of adequate understanding
concerned items speciﬁc to the CLEAR NPT such as co-
interventions, speciﬁc methods to avoid ascertainment bias,
and participant adherence but also items assessed in most
quality tools such as allocation concealment, intention-to-
treat analysis, and blinding of outcome assessors, which are
key weapons in the ﬁght against bias. For example, a debate
arose when considering the results of the Balk et al. series,
because the authors considered that an opaque sealed
envelope was an adequate method of allocation concealment
[4,26]. These results need to be highlighted, considering the
high degree of expertise our participants have in the ﬁeld of
peer review and point out the need for education on these
topics among the scientiﬁc community.
The reproducibility of the items speciﬁc to the CLEAR
NPT could probably be improved upon with a modiﬁcation
of the wording of these items. The item ‘‘Was participants
adherence assessed quantitatively?’’ could be clariﬁed with
the following wording ‘‘Was participants adherence reported
quantitatively in the results section?’’. Furthermore, the item
on co-interventions, which requires that the description of
the co-intervention be provided in the results section not
only in the methods section, could be modiﬁed as follows:
‘‘Were all other treatments or care as described in the results
section the same in each randomised group?’’
Our results show that the item ‘‘Was the treatment
allocation concealed?’’ had fewer than 50% of correct
answers. These results are probably linked to the lack of
consistency of the deﬁnition of allocation concealment. Pildal
et al. [27] recognized that, depending on the reviewer, strict
or loose criteria could be used to deﬁne allocation conceal-
ment. According to the deﬁnition used, sealed envelopes not
reported as opaque would be considered as an adequate or
inadequate method of concealment. In our study, we deﬁned
allocation concealment according to strict criteria, as Schulz
.......................................................................................................................................................................................
Table 2. Rate of Correct Answers Per Group Per Item
Item Question n Percent Mean
Rate of
Agreement
Paired
Agreement
n (%)
Paired
Disagreement
n (%)
Intervention
Agreement
Only n (%)
Control
Agreement
Only n (%)
p-
Value
a
1 Was the generation of allocation sequences adequate? 39 79.5 25 (64.1) 2 (5.1) 7 (18.0) 5 (12.8) 0.56
2 Was the treatment allocation concealed? 39 46.1 10 (25.6) 13 (33.3) 6 (15.4) 10 (25.6) 0.18
3 Were details of the intervention administered to each
group made available?
39 82.0 28 (71.8) 3 (7.7) 5 (12.8) 3 (7.7) 0.72
4 Were care providers’ experience or skill in each arm
appropriate?
39 65.4 18 (46.2) 6 (15.4) 9 (23.1) 6 (15.4) 0.44
5 Was participant (i.e., patient’s) adherence assessed
quantitatively ?
39 61.5 17 (43.6) 8 (20.5) 4 (10.3) 10 (25.6) 0.11
6 Were participants adequately blinded? 39 79.5 27 (69.2) 4 (10.3) 5 (12.8) 3 (7.7) 0.72
7 Were care providers or people caring for the
participants adequately blinded?
39 78.2 27 (69.2) 5 (12.8) 3 (7.7) 4 (10.3) 0.71
6.1/7.1 Were all other treatments and care (i.e., co-interventions)
the same in each randomised group?
38 30.3 5 (13.2) 20 (52.6) 5 (13.2) 8 (21.0) 0.13
6.2/7.2 Were withdrawals and lost-to-follow-up the same in
each randomised group?
38 65.8 18 (47.4) 6 (15.8) 8 (21.0) 6 (15.8) 0.80
8 Were outcome assessors adequately blinded to assess
the primary outcomes?
39 53.8 13 (33.3) 10 (25.6) 9 (23.1) 7 (18.0) 0.62
8.1 If outcome assessors were not adequately blinded, were
specific methods used to avoid ascertainment bias?
21 28.6 2 (9.5) 11 (52.4) 3 (14.3) 5 (23.8) 0.72
9 Was the follow-up schedule the same in each group? 39 83.3 29 (74.4) 3 (7.7) 5 (12.8) 2 (5.1) 0.35
10 Were the main outcomes analysed according to the
intention-to-treat principle?
39 60.2 20 (51.3) 12 (30.8) 3 (7.7) 4 (10.3) 0.7
Paired agreement supposes that participants in the intervention and in the control groups agreed with the gold standard. Paired disagreement supposes that both participants in the
intervention and control group disagreed with the gold standard. Intervention agreement and control agreement indicate, respectively, that only the participant in the intervention
group agreed with the gold standard, and that only the participant of the control group agreed with the gold standard.
aThe ‘‘per item rate’’ of correct answers to the criterion standard was compared by use of a McNemar test for paired dichotomous data and with Yates correction when appropriate. A
p-value   0.05 was considered statistically significant, and all tests were two-sided.
doi:10.1371/journal.pctr.0020022.t002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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et al. related regarding deciphering the allocation sequence
by taking the nonopaque sealed envelopes to a ‘‘hot light’’
[28]. Some reviewers require an even more strict deﬁnition of
allocation concealment with the need to report who prepared
the envelopes. In fact, if the same person prepared the
envelopes and recruited the patients, the allocation would
not be adequately concealed.
Blinding of the outcome assessors was also poorly rated.
These results concerned mainly trials in which the main
outcome was a patient-reported outcome but patients were
not reported as blinded. Therefore, the outcome assessor (i.e.,
the patient) could not be considered as adequately blinded
even if the authors mentioned the presence of a blinded data
collector who questioned the patients.
Only 60% of participants were in agreement with the
criterion standard for the item related to intention-to-treat
analysis. These results are probably linked to the poor
reporting of this issue [17,29]. Baron et al. [30] showed that,
in a panel of 81 reports, 66.7% described an intention-to-
treat analysis, but full intention to treat was performed in
only 7.4% of the studies.
These results are consistent with other studies. Maher et al.
[31] evaluated the reliability of the ten-item Physiotherapy
Evidence-Based Database (PEDro) scales and found kappa
scores ranging from 0.12 to 0.73 (0.36 to 0.80 for individual
assessors) for items, with low concordance on intention-to-
treat analysis and therapist blinding. Clark et al.[16] showed a
poor interrater agreement (kappa score range 0.37–0.39) for
the Jadad scale.
Limitations
The validity of the criterion standard used to assess raters’
performance when using the CLEAR NPT could be a
limitation. However, this standard was developed by three
reviewers, two of whom were involved in the elaboration of
the CLEAR NPT. They evaluated all 39 reports independently
and according to the user’s guide. They discussed all the
discrepancies to come to a consensus.
Generalisability
Another limitation is related to the rate of participation: 84%
of reviewers approached did not participate. The time
necessary to participate in this trial could likely explain
these results. This may limit the generalisability of the results.
Finally, the baseline distribution of reviewers was imbal-
anced, with more experienced meta-analysts randomised to
the control group. The effect of this potential baseline
imbalance could dilute the intervention effect.
In conclusion, in this study, we attempted to improve the
understanding of a quality checklist that evaluates reports of
nonpharmacological trials, the CLEAR NPT, with an ICLS.
Although this pedagogical tool did not improve participants’
performance in using the checklist, our results highlight the
lack of consistent understanding of some of the key weapons
in the ﬁght against bias. There is an urgent need for speciﬁc
training to improve the understanding of such quality tools.
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